Impaired Exercise Tolerance Early After Heart Transplantation Is Associated With Development of Cardiac Allograft Vasculopathy

被引:1
|
作者
Yu, Mingxi D. [1 ]
Liebo, Max J. [1 ]
Lundgren, Scott [2 ]
Salim, Ahmed M. [2 ]
Joyce, Cara [1 ]
Zolty, Ronald [2 ]
Moulton, Michael J. [2 ]
Um, John Y. [2 ]
Lowes, Brian D. [2 ]
Raichlin, Eugenia [1 ,2 ]
机构
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
关键词
CORONARY-ARTERY-DISEASE; ANTIBODY-MEDIATED REJECTION; INTERNATIONAL SOCIETY; WORKING FORMULATION; CHRONOTROPIC INCOMPETENCE; VENTILATORY EFFICIENCY; PATHOLOGICAL DIAGNOSIS; DIASTOLIC DYSFUNCTION; OXYGEN-CONSUMPTION; VE/VCO2; SLOPE;
D O I
10.1097/TP.0000000000003110
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Exercise performance remains limited in some patients after heart transplantation (HTx). The goal of this study was to assess for association between cardiopulmonary exercise test performance at 1 year after HTx and future development of cardiac allograft vasculopathy (CAV). Methods. Overall 243 HTx recipients performed cardiopulmonary exercise testing at 1 year after HTx. During the median follow-up period of 31 (interquartile range 19;61) months, 76 (32%) patients were diagnosed with CAV (CAV group). Results. The CAV group patients had lower exercise capacity (5.2 +/- 1.9 versus 6.5 +/- 2.2 metabolic equivalents;P= 0.001) and duration (9.6 +/- 3.5 versus 11.4 +/- 4.8 min;P= 0.008), lower peak oxygen consumption (VO2) (18.4 +/- 5.4 versus 21.4 +/- 6.1 mL/kg/min;P= 0.0005), lower normalized peak VO2(63% +/- 18% versus 71% +/- 19%;P= 0.007), and higher minute ventilation (VE)/carbon dioxide production (VCO2) (34 +/- 5 versus 32 +/- 5,P= 0.04). On Cox proportional hazards regression analysis, normalized peak VO2 <= 60%, and VE/VCO2 >= 34 were associated with a high hazard for CAV (HR = 1.8 [95% CI 1.10-4.53,P= 0.03] and 2.5 [95% CI 1.01-8.81,P= 0.04], respectively). The subgroup of patients with both normalized peak VO2 <= 60% and VE/VCO2 >= 34 was at highest risk for development of CAV (HR = 5.2, 95% CI 2.27-15.17,P= 0.001). Conclusions. Normalized peak VO2 <= 60% and VE/VCO2 >= 34 at 1 year after HTx are associated with the development of CAV.
引用
收藏
页码:2196 / 2203
页数:8
相关论文
共 50 条
  • [11] Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation
    Delgado, Juan F.
    Garcia Reyne, Ana
    de Dios, Santiago
    Lopez-Medrano, Francisco
    Jurado, Alfonso
    San Juan, Rafael
    Jose Ruiz-Cano, Maria
    Dolores Folgueira, M.
    Angel Gomez-Sanchez, Miguel
    Maria Aguado, Jose
    Lumbreras, Carlos
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (08): : 1112 - 1119
  • [12] Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation
    Bergmark, Brian A.
    Zelniker, Thomas A.
    Kim, Miae
    Mehra, Mandeep R.
    Stewart, Garrick C.
    Page, Deborah S.
    Woodcome, Erica L.
    Givertz, Michael M.
    CLINICAL TRANSPLANTATION, 2021, 35 (10)
  • [13] Cardiac allograft vasculopathy after heart transplantation: Is it really ominous?
    Lim, Ju Yong
    Jung, Sung Ho
    Kim, Min Seok
    Park, Jeong-Jun
    Yun, Tae-Jin
    Kim, Jae Joong
    Lee, Jae Won
    CLINICAL TRANSPLANTATION, 2017, 31 (02)
  • [14] Accelerated cardiac allograft vasculopathy after pediatric heart transplantation
    Zablah, Jenny E.
    Everitt, Melanie D.
    Wilson, Neil
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (11) : 2984 - 2985
  • [15] PET Assessment of Cardiac Allograft Vasculopathy After Heart Transplantation
    Asleh, Rabea
    Kushwaha, Sudhir S.
    JACC-HEART FAILURE, 2023, 11 (05) : 566 - 568
  • [16] The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation
    Spitaleri, Giosafat
    Farrero Torres, Marta
    Sabatino, Mario
    Potena, Luciano
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (11) : 1367 - 1376
  • [17] Medication Management of Cardiac Allograft Vasculopathy After Heart Transplantation
    Hollis, Ian B.
    Reed, Brent N.
    Moranville, Michael P.
    PHARMACOTHERAPY, 2015, 35 (05): : 489 - 501
  • [18] Cardiac Allograft Remodeling After Heart Transplantation Is Associated with Increased Graft Vasculopathy and Mortality
    Raichlin, E.
    Villarraga, H. R.
    Chandrasekaran, K.
    Clavell, A. L.
    Frantz, R. P.
    Kushwaha, S. S.
    Rodeheffer, R. J.
    McGregor, C. G.
    Daly, R. C.
    Park, S. J.
    Kremers, W. K.
    Edwards, B. S.
    Pereira, N. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (01) : 132 - 139
  • [19] Hepatitis B Seropositivity is Associated with Increased Cardiac Allograft Vasculopathy after Heart Transplantation
    Peled, Y.
    Lavee, J.
    Maor, E.
    Freimark, D.
    Sternik, L.
    Ram, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S479 - S479
  • [20] Lung function and cardiopulmonary exercise performance after heart transplantation -: Influence of cardiac allograft vasculopathy
    Schwaiblmair, M
    von Scheidt, W
    Überfuhr, P
    Reichart, B
    Vogelmeier, C
    CHEST, 1999, 116 (02) : 332 - 339